Skip to content
StackItSmart
BHuman cohort / observational
High risk

Human Growth Hormone

HGH · Somatropin · GH

Human growth hormone (HGH, somatropin) is a 191-amino-acid peptide hormone produced as recombinant human GH (rhGH). It is an approved therapy for genuine GH deficiency and a few wasting/growth disorders, but it is widely misused off-label for anti-aging, body composition, and athletic purposes. The evidence-based reality is unflattering: a systematic review of randomized trials in fit young adults found GH raises lean body mass (~2 kg, substantially fluid/water) but does not improve strength or aerobic capacity, and may actually worsen exercise capacity while increasing side effects. The main dangers come from chronic supraphysiologic exposure, which mimics acromegaly, a disease of GH/IGF-1 excess associated with cardiomyopathy, hypertension, insulin resistance/diabetes, soft-tissue overgrowth, sleep apnea, arthropathy, and increased mortality that normalizes only when GH/IGF-1 are brought back to normal. Acute risks include fluid retention, carpal tunnel/nerve compression, arthralgias, and severe hypoglycemia, especially when stacked with insulin or IGF-1. Long-term safety in healthy people using it for enhancement has never been established in controlled trials; the harm profile is largely extrapolated from acromegaly and GH-replacement surveillance. This is not medical advice; anyone using or considering HGH should work with a physician/endocrinologist and monitor bloodwork.

Clinical readoutPeptide · growth-hormone
Hepatic strainLow
CardiovascularModerate
HPTA suppressionNone
Half-life
3 h
Route
Subcutaneous injection…
Evidence
B
Active
Metabolic/anabolic acti…
3 h6 h9 h12 h15 h
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ After subcutaneous injection the circulating half-life of somatropin is short (roughly 2-4 hours, absorption-rate-limited), but the downstream biological signal is far longer-lived: GH-driven IGF-1 remains elevated on the order of a day, and connective-tissue/collagen turnover markers stay elevated for weeks. In a controlled trial, serum IGF-axis markers returned toward baseline within about 1 week after stopping, while collagen markers (e.g., PIIINP) remained elevated at ~6 weeks. This washout information is provided for monitoring and clinical interpretation, not for evading anti-doping tests.
Pharmacology

Mechanism of action

GH binds the transmembrane GH receptor (a JAK2/STAT5-signaling cytokine receptor), primarily in the liver, driving hepatic production and secretion of insulin-like growth factor-1 (IGF-1), which mediates most of the anabolic and growth-promoting effects (stimulation of muscle protein synthesis, chondrocyte/bone growth, cell proliferation). GH also exerts direct, IGF-1-independent metabolic actions: it is lipolytic (mobilizes free fatty acids), antagonizes insulin action (promoting insulin resistance and hyperglycemia), promotes renal sodium/water retention, and stimulates collagen/connective-tissue turnover. In enhancement misuse the intended targets are the IGF-1-mediated anabolic and the direct lipolytic effects; the same pathways drive the adverse effects when GH/IGF-1 are chronically elevated above physiologic range.
Kinetics

Pharmacokinetics

Half-life

After subcutaneous injection the circulating half-life of somatropin is short (roughly 2-4 hours, absorption-rate-limited), but the downstream biological signal is far longer-lived: GH-driven IGF-1 remains elevated on the order of a day, and connective-tissue/collagen turnover markers stay elevated for weeks. In a controlled trial, serum IGF-axis markers returned toward baseline within about 1 week after stopping, while collagen markers (e.g., PIIINP) remained elevated at ~6 weeks. This washout information is provided for monitoring and clinical interpretation, not for evading anti-doping tests.

Active duration

Metabolic/anabolic actions outlast the parent hormone because they are mediated by IGF-1 and tissue remodeling: effective biological duration is on the order of ~24 hours per dose for IGF-1 effects, with collagen-turnover effects persisting for weeks after cessation.

Route

Subcutaneous injection is the usual route (some regimens use intramuscular). Oral administration is not effective because the peptide is digested.

Metabolism & clearance

Cleared by receptor-mediated uptake and proteolytic degradation in the liver and kidneys (the kidney is a major site of GH catabolism); it is a peptide broken down to amino acids rather than metabolized by cytochrome P450. Downstream effects are propagated through hepatic IGF-1 production.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Increases lean body mass (in RCTs of healthy young adults ~2.1 kg vs control), but a substantial fraction is extracellular fluid/water rather than functional muscle
  • Reduces fat mass / promotes lipolysis
  • Does not improve muscle strength or power in controlled trials
  • Does not improve, and may worsen, aerobic/endurance exercise capacity; blood lactate during exercise is higher
  • May modestly increase anaerobic capacity in some studies (not consistent, not proven to translate to athletic performance)
  • Raises circulating IGF-1 and collagen turnover markers (used as anti-doping biomarkers)
  • Genuine GH deficiency is a distinct, physician-diagnosed and monitored medical condition treated under specialist care; that treatment context does not generalize to GH-replete healthy users seeking enhancement, who face a different risk-benefit balance and no comparable evidence of benefit
Safety

Adverse effects by system

Cardiovascular

Chronic GH/IGF-1 excess (acromegaly) is associated with concentric cardiomyopathy, hypertension, cardiac dysfunction and increased cardiovascular mortality; fluid retention can raise blood pressure. Long-term cardiovascular risk from enhancement-pattern misuse in healthy people has not been studied and is extrapolated from acromegaly and surveillance data.

Hepatic

Not a recognized direct hepatotoxin; rhGH is not associated with drug-induced liver injury in the way oral 17-alpha-alkylated steroids are. No adequate data indicate clinically significant hepatocellular toxicity from GH itself.

Endocrine / HPTA

GH antagonizes insulin action, causing insulin resistance, glucose intolerance and can precipitate or unmask type 2 diabetes; it does not act on the gonadal (HPG) axis. Exogenous GH suppresses endogenous pituitary GH secretion via IGF-1 negative feedback. Can lower free thyroxine/unmask central hypothyroidism and alter cortisol metabolism.

Reproductive

No direct suppression of the reproductive/HPG axis and GH is not androgenic; fertility effects specific to GH misuse are not well characterized. In acromegaly, associated pituitary pathology or hyperprolactinemia can impair gonadal function, but that reflects the tumor, not GH per se.

Neuropsychiatric

No consistent, well-established psychiatric syndrome attributable to GH; fatigue is reported more often in GH-treated trial participants. Robust human data on mood/psychiatric effects in enhancement users are lacking.

Renal

GH promotes renal sodium and water retention causing peripheral edema; it increases GFR and renal plasma flow. No direct nephrotoxicity established, but fluid retention and blood-pressure effects are relevant to renal/cardiovascular load.

Hematologic

No well-established clinically significant hematologic toxicity attributable to GH in the primary literature; no adequate human data specific to enhancement misuse.

Dermatologic

Injection-site reactions/lipoatrophy possible; soft-tissue overgrowth in chronic excess (acromegaly) causes skin thickening, coarsening of features, and increased sweating/oily skin. Enhancement-user-specific dermatologic data are limited.

Recovery

HPTA suppression & recovery

Suppression: Not applicable to the gonadal (testosterone) axis — GH is not androgenic and does not suppress hypothalamic-pituitary-gonadal function. Exogenous GH does suppress endogenous pituitary GH output via IGF-1 negative feedback.

Because GH does not suppress the HPG axis, SERM-based post-cycle/recovery protocols are not indicated for GH and this monograph does not describe any SERM regimen for it. Recovery of endogenous GH secretion after stopping exogenous GH, and evaluation of any pituitary or glucose abnormalities, should be assessed and managed by an endocrinologist rather than self-directed. Anyone with symptoms of hormonal dysfunction should seek endocrinology care.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Serum IGF-1 (to detect supraphysiologic exposure)Fasting glucose and HbA1c (glucose intolerance/diabetes)Fasting insulin / HOMA-IRLipid panelBlood pressureThyroid function (free T4, TSH)Consider fasting glucose before and during if combined with any insulin — hypoglycemia risk

Cadence: Baseline before any use, then periodically (e.g., every 3-6 months) under a physician; sooner if symptomatic. Any combination with insulin or IGF-1 demands close medical supervision due to hypoglycemia risk.

Warning signs — seek care
  • Persistent hand/wrist numbness or tingling (carpal tunnel / nerve compression)
  • Swelling of hands, feet, or face (fluid retention)
  • New or worsening joint pain
  • Symptoms of high blood sugar (excess thirst, urination) or of hypoglycemia (sweating, confusion, palpitations—especially if combined with insulin/IGF-1)
  • Enlarging hands/feet/jaw, coarsening facial features, or dental spacing (acromegalic change)
  • Headache with visual changes
  • New or worsening snoring / daytime somnolence (sleep apnea)
  • Chest pain, breathlessness, or exertional intolerance
Do not use if

Contraindications

  • Active malignancy or history of cancer (GH/IGF-1 are mitogenic; GH is contraindicated with active tumor)
  • Active proliferative or severe diabetic retinopathy
  • Acute critical illness (increased mortality shown with GH in critically ill patients)
  • Diabetes mellitus or impaired glucose tolerance (GH worsens insulin resistance) — requires specialist oversight
  • Untreated/active acromegaly or pituitary tumor
  • Benign intracranial hypertension
  • Known hypersensitivity to somatropin or excipients
  • Severe obesity or uncontrolled sleep apnea (relative; can worsen)
  • Concurrent insulin or IGF-1 use without medical supervision (high hypoglycemia risk)
Combinations

Interaction profile

  • ModerateWith an anabolic steroid: Additive cardiovascular strain
  • MajorWith insulin: Metabolic / glucose
  • ModerateWith a GH secretagogue: Metabolic / glucose
  • ModerateWith IGF-1: Metabolic / glucose
  • ModerateWith a GLP-1 / incretin agonist: Metabolic / glucose
  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • The controlled evidence shows GH does not improve strength or endurance in healthy people, so the expected performance benefit does not justify the risks.
  • Never combine GH with insulin or IGF-1 without direct medical supervision — this combination is a leading cause of severe, potentially fatal hypoglycemia.
  • Get baseline and periodic bloodwork (IGF-1, fasting glucose/HbA1c, lipids) and blood pressure with a physician; supraphysiologic IGF-1 is a signal to stop.
  • Stop and seek medical care for hand/wrist numbness (carpal tunnel), significant swelling, joint pain, symptoms of high or low blood sugar, visual changes with headache, or new/worsening sleep apnea.
  • Watch for acromegalic changes (enlarging hands/feet/jaw, coarsening features) — these indicate chronic overexposure and warrant stopping and endocrinology evaluation.
  • People with cancer history, diabetes/prediabetes, retinopathy, or acute serious illness should not use GH.
  • Any hormonal, glucose, or pituitary concerns should be evaluated by an endocrinologist; do not self-manage recovery.
  • This information is educational harm-reduction, not an endorsement of use or a substitute for medical care.
Evidence

Citations (11)

Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.

  1. 01

    In RCTs of physically fit young adults, GH increased lean body mass (~2.1 kg) but did not improve strength or exercise capacity, may worsen exercise capacity, raised exercise lactate, and increased soft-tissue edema and fatigue.

    Meta-analysisSystematic review: the effects of growth hormone on athletic performance.PMID 18347346 ↗

  2. 02

    Randomized double-blind placebo-controlled trial administered GH 2 mg/day subcutaneously for 8 weeks to recreational athletes; GH raised IGF-1 and collagen markers, IGF markers returned to baseline within ~1 week while collagen markers remained elevated ~6 weeks (washout/detection window).

    RCTPMID 18381573 ↗

  3. 03

    In healthy older men, GH (dose titrated to upper-normal IGF-1) increased lean body mass and decreased fat but produced variable/minimal strength gains; combined GH+testosterone increased midthigh muscle and aerobic capacity.

    RCTPMID 16332938 ↗

  4. 04

    Evidence indicates GH does not enhance muscle strength, power, or aerobic capacity in healthy adults; increased lean mass is partly fluid retention; sustained abuse can produce an acromegaly-like state with increased morbidity and mortality; GH may increase anaerobic capacity.

    ReviewPMID 20122446 ↗

  5. 05

    GH is widely abused despite limited performance evidence; long-term GH excess carries adverse effects mimicking acromegaly, a condition of increased morbidity and mortality.

    ReviewPMID 21420315 ↗

  6. 06

    Athletes self-administering large doses of GH (often combined with anabolic steroids and insulin) expose themselves to harm; effects of excess GH are exemplified by acromegaly, and combination with insulin or IGF-1 can cause profound hypoglycemia.

    ReviewGrowth hormone, IGF-I and insulin and their abuse in sportPMID 18376417 ↗

  7. 07

    rHGH benefits in otherwise-healthy adults are uncertain; GH excess may cause acromegaly; therapeutic value is established mainly for GH deficiency.

    ReviewThe Use and Abuse of Human Growth Hormone in Sports.PMID 29932857 ↗

  8. 08

    Chronic GH/IGF-1 excess (acromegaly) produces cardiovascular, cerebrovascular, and pulmonary dysfunction and reduced life expectancy, improved by lowering GH/IGF-1.

    ReviewGrowth Hormone Excess: Implications and Management.PMID 36237164 ↗

  9. 09

    Meta-analysis: acromegaly mortality (SMR) is elevated (~1.9 with GH >2.5 ug/L; ~2.5 with persistently elevated IGF-1) and normalizes (~1.1) when GH and IGF-1 are controlled, demonstrating GH/IGF-1 excess drives excess mortality.

    Meta-analysisA meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly.PMID 18524797 ↗

  10. 10

    GH-replacement surveillance (KIMS): median therapeutic dose ~0.3 mg/day; a cohort with prior GH excess showed increased cardiovascular mortality (SMR 3.03); no difference in cancer or diabetes incidence between GH-replaced cohorts in this analysis.

    CohortPMID 24694339 ↗

  11. 11

    IGF-1 mediates many anabolic actions of GH (muscle protein synthesis, glycogen storage, lipolysis); long-term adverse effects of IGF-1/GH misuse are largely unknown and extrapolated from chronic GH excess.

    ReviewPMID 20443773 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice